Identification
NameDasatinib
Accession NumberDB01254
TypeSmall Molecule
GroupsApproved, Investigational
Description

Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.

Structure
Thumb
Synonyms
anh. dasatinib
Anhydrous dasatinib
BMS dasatinib
Dasatinib
Dasatinib (anh.)
dasatinib (anhydrous)
Dasatinibum
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
External IDs BMS-354825
Product Ingredients
IngredientUNIICASInChI KeyDetails
Dasatinib monohydrateRBZ1571X5H 863127-77-9XHXFZZNHDVTMLI-UHFFFAOYSA-NDetails
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SprycelTablet50 mg/1OralE.R. Squibb & Sons, L.L.C.2006-06-27Not applicableUs
SprycelTablet, film coated50 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet, film coated140 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet70 mg/1OralPhysicians Total Care, Inc.2007-02-12Not applicableUs
SprycelTablet, film coated70 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet70 mgOralBristol Myers Squibb2007-04-13Not applicableCanada
SprycelTablet, film coated70 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet140 mg/1OralE.R. Squibb & Sons, L.L.C.2010-10-28Not applicableUs
SprycelTablet, film coated50 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet20 mg/1OralE.R. Squibb & Sons, L.L.C.2006-06-27Not applicableUs
SprycelTablet140 mgOralBristol Myers Squibb2011-03-29Not applicableCanada
SprycelTablet, film coated80 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet, film coated20 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet100 mg/1OralE.R. Squibb & Sons, L.L.C.2008-05-30Not applicableUs
SprycelTablet, film coated70 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet, film coated140 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet20 mgOralBristol Myers Squibb2007-04-13Not applicableCanada
SprycelTablet100 mgOralBristol Myers Squibb2009-05-04Not applicableCanada
SprycelTablet, film coated100 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet, film coated80 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet, film coated20 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet50 mgOralBristol Myers Squibb2007-04-13Not applicableCanada
SprycelTablet, film coated50 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet80 mg/1OralE.R. Squibb & Sons, L.L.C.2010-10-28Not applicableUs
SprycelTablet, film coated20 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet70 mg/1OralE.R. Squibb & Sons, L.L.C.2006-06-27Not applicableUs
SprycelTablet80 mgOralBristol Myers Squibb2011-09-02Not applicableCanada
SprycelTablet, film coated100 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIIX78UG0A0RN
CAS number302962-49-8
WeightAverage: 488.006
Monoisotopic: 487.155721508
Chemical FormulaC22H26ClN7O2S
InChI KeyZBNZXTGUTAYRHI-UHFFFAOYSA-N
InChI
InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
IUPAC Name
N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
SMILES
CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Pharmacology
Indication

For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.

Structured Indications
Pharmacodynamics

Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor

Mechanism of action

Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.

TargetKindPharmacological actionActionsOrganismUniProt ID
Tyrosine-protein kinase ABL1Proteinyes
multitarget
HumanP00519 details
Proto-oncogene tyrosine-protein kinase SrcProteinyes
multitarget
HumanP12931 details
Ephrin type-A receptor 2Proteinyes
antagonist
HumanP29317 details
Tyrosine-protein kinase LckProteinyes
multitarget
HumanP06239 details
Tyrosine-protein kinase YesProteinyes
inhibitor
HumanP07947 details
Mast/stem cell growth factor receptor KitProteinunknown
antagonist
HumanP10721 details
Platelet-derived growth factor receptor betaProteinunknown
antagonist
HumanP09619 details
Signal transducer and activator of transcription 5BProteinunknown
inhibitor
HumanP51692 details
Abelson tyrosine-protein kinase 2Proteinunknown
multitarget
HumanP42684 details
Tyrosine-protein kinase FynProteinunknown
multitarget
HumanP06241 details
Tyrosine-protein kinase BTKProteinunknownNot AvailableHumanQ06187 details
Nuclear receptor subfamily 4 group A member 3ProteinunknownNot AvailableHumanQ92570 details
Breakpoint cluster region proteinProteinunknownNot AvailableHumanP11274 details
Tyrosine-protein kinase CSKProteinunknownNot AvailableHumanP41240 details
Ephrin type-A receptor 5ProteinunknownNot AvailableHumanP54756 details
Ephrin type-B receptor 4ProteinunknownNot AvailableHumanP54760 details
Tyrosine-protein kinase FgrProteinunknownNot AvailableHumanP09769 details
Tyrosine-protein kinase FRKProteinunknownNot AvailableHumanP42685 details
Heat shock cognate 71 kDa proteinProteinunknownNot AvailableHumanP11142 details
Tyrosine-protein kinase LynProteinunknownNot AvailableHumanP07948 details
Mitogen-activated protein kinase kinase kinase MLTProteinunknownNot AvailableHumanQ9NYL2 details
Mitogen-activated protein kinase 14ProteinunknownNot AvailableHumanQ16539 details
AmidophosphoribosyltransferaseProteinunknownNot AvailableHumanQ06203 details
Related Articles
AbsorptionNot Available
Volume of distribution
  • 2505 L
Protein binding

96%

Metabolism

Dasatinib is extensively metabolized in humans, primarily by the cytochrome P450 enzyme 3A4

Route of elimination

Dasatinib is extensively metabolized in humans, primarily by the cytochrome P450 enzyme 3A4. Elimination is primarily via the feces.

Half life

The overall mean terminal half-life of dasatinib is 3-5 hours.

ClearanceNot Available
Toxicity

Acute overdose in animals was associated with cardiotoxicity.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Dasatinib Inhibition of BCR-ABLDrug actionSMP31696
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbciximabDasatinib may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Dasatinib can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Dasatinib.Approved
AcenocoumarolDasatinib may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenAcetaminophen may increase the hepatotoxic activities of Dasatinib.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Dasatinib.Approved
Acetylsalicylic acidDasatinib may increase the anticoagulant activities of Acetylsalicylic acid.Approved, Vet Approved
AdinazolamThe serum concentration of Adinazolam can be increased when it is combined with Dasatinib.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Dasatinib.Approved
AlbendazoleThe serum concentration of Albendazole can be increased when it is combined with Dasatinib.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Dasatinib.Approved
AldosteroneThe serum concentration of Dasatinib can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Dasatinib can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Dasatinib.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Dasatinib.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Dasatinib.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Dasatinib.Approved, Investigational
AllylestrenolThe serum concentration of Allylestrenol can be increased when it is combined with Dasatinib.Approved
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Dasatinib.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be increased when it is combined with Dasatinib.Approved
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Dasatinib.Approved, Withdrawn
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Dasatinib.Approved, Illicit, Investigational
AlprostadilDasatinib may increase the anticoagulant activities of Alprostadil.Approved, Investigational
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmantadineThe serum concentration of Dasatinib can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Dasatinib.Approved, Investigational
AmbroxolThe serum concentration of Ambroxol can be increased when it is combined with Dasatinib.Approved
Aminohippuric acidThe serum concentration of Dasatinib can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe serum concentration of Aminophenazone can be increased when it is combined with Dasatinib.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Dasatinib.Approved
AmiodaroneThe serum concentration of Dasatinib can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Dasatinib.Approved
AmlodipineThe serum concentration of Amlodipine can be increased when it is combined with Dasatinib.Approved
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Dasatinib.Approved
AmsacrineThe serum concentration of Dasatinib can be increased when it is combined with Amsacrine.Approved
AnagrelideDasatinib may increase the anticoagulant activities of Anagrelide.Approved
AncrodDasatinib may increase the anticoagulant activities of Ancrod.Investigational
AntipyrineThe serum concentration of Antipyrine can be increased when it is combined with Dasatinib.Approved
Antithrombin III humanDasatinib may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanDasatinib may increase the anticoagulant activities of Apixaban.Approved
ApremilastThe serum concentration of Apremilast can be increased when it is combined with Dasatinib.Approved, Investigational
AprepitantThe serum concentration of Dasatinib can be increased when it is combined with Aprepitant.Approved, Investigational
ArdeparinDasatinib may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanDasatinib may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Dasatinib.Approved, Investigational
Arsenic trioxideDasatinib may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe serum concentration of Artemether can be increased when it is combined with Dasatinib.Approved
AsenapineAsenapine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Dasatinib.Approved, Withdrawn
AtazanavirThe serum concentration of Dasatinib can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Dasatinib can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Dasatinib can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Dasatinib.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Dasatinib.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Dasatinib.Approved, Investigational
AzelastineDasatinib may increase the anticoagulant activities of Azelastine.Approved
AzithromycinThe serum concentration of Azithromycin can be increased when it is combined with Dasatinib.Approved
BanoxantroneThe serum concentration of Banoxantrone can be increased when it is combined with Dasatinib.Investigational
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Dasatinib.Investigational
BecaplerminDasatinib may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Dasatinib.Approved
BenzocaineThe serum concentration of Dasatinib can be increased when it is combined with Benzocaine.Approved
BenzphetamineThe serum concentration of Benzphetamine can be increased when it is combined with Dasatinib.Approved, Illicit
Benzyl alcoholThe serum concentration of Benzyl alcohol can be increased when it is combined with Dasatinib.Approved
BepridilThe serum concentration of Dasatinib can be increased when it is combined with Bepridil.Approved, Withdrawn
BeraprostDasatinib may increase the anticoagulant activities of Beraprost.Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Dasatinib.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Dasatinib.Approved, Investigational
BexaroteneThe serum concentration of Bexarotene can be increased when it is combined with Dasatinib.Approved, Investigational
BezafibrateThe serum concentration of Bezafibrate can be increased when it is combined with Dasatinib.Approved
BicalutamideThe serum concentration of Bicalutamide can be increased when it is combined with Dasatinib.Approved
BiperidenThe serum concentration of Dasatinib can be increased when it is combined with Biperiden.Approved
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Dasatinib.Approved
BivalirudinDasatinib may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Dasatinib can be increased when it is combined with Boceprevir.Withdrawn
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Dasatinib.Approved, Investigational
BosentanThe serum concentration of Dasatinib can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Dasatinib.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dasatinib.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Dasatinib.Approved
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Dasatinib.Approved
BromazepamThe serum concentration of Bromazepam can be increased when it is combined with Dasatinib.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Dasatinib.Approved, Investigational
BrompheniramineThe serum concentration of Brompheniramine can be increased when it is combined with Dasatinib.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Dasatinib.Approved
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Dasatinib.Approved, Investigational
BuprenorphineThe serum concentration of Buprenorphine can be increased when it is combined with Dasatinib.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be increased when it is combined with Dasatinib.Approved
BuspironeThe serum concentration of Buspirone can be increased when it is combined with Dasatinib.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Dasatinib.Approved, Investigational
ButylphthalideDasatinib may increase the anticoagulant activities of Butylphthalide.Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Dasatinib.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Dasatinib.Approved
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Dasatinib.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Dasatinib.Approved
CalcitriolThe serum concentration of Calcitriol can be increased when it is combined with Dasatinib.Approved, Nutraceutical
Calcium CarbonateCalcium carbonate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Dasatinib.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Dasatinib.Approved
CandesartanThe serum concentration of Dasatinib can be increased when it is combined with Candesartan.Approved
CangrelorDasatinib may increase the anticoagulant activities of Cangrelor.Approved
CaptoprilThe serum concentration of Dasatinib can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Dasatinib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe serum concentration of Carbinoxamine can be increased when it is combined with Dasatinib.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Dasatinib.Approved
CariprazineThe serum concentration of Cariprazine can be increased when it is combined with Dasatinib.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Dasatinib.Approved, Investigational
CaspofunginThe serum concentration of Dasatinib can be increased when it is combined with Caspofungin.Approved
CelecoxibThe serum concentration of Celecoxib can be increased when it is combined with Dasatinib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Dasatinib.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be increased when it is combined with Dasatinib.Approved, Vet Approved
CeritinibThe serum concentration of Dasatinib can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Dasatinib.Withdrawn
CertoparinDasatinib may increase the anticoagulant activities of Certoparin.Approved
CevimelineThe serum concentration of Cevimeline can be increased when it is combined with Dasatinib.Approved
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be increased when it is combined with Dasatinib.Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be increased when it is combined with Dasatinib.Approved, Illicit
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Dasatinib.Approved, Vet Approved
ChlorphenamineThe serum concentration of Chlorphenamine can be increased when it is combined with Dasatinib.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Dasatinib.Approved, Vet Approved
ChlorpropamideThe serum concentration of Dasatinib can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Dasatinib can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be increased when it is combined with Dasatinib.Approved
CholecalciferolThe serum concentration of Cholecalciferol can be increased when it is combined with Dasatinib.Approved, Nutraceutical
CholesterolThe serum concentration of Dasatinib can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Dasatinib can be decreased when it is combined with Cholic Acid.Approved
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Dasatinib.Approved, Investigational
CilazaprilThe serum concentration of Dasatinib can be increased when it is combined with Cilazapril.Approved
CilostazolDasatinib may increase the anticoagulant activities of Cilostazol.Approved
CimetidineCimetidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinacalcetThe serum concentration of Cinacalcet can be increased when it is combined with Dasatinib.Approved
CiprofloxacinDasatinib may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Dasatinib.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Dasatinib.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Dasatinib.Approved
Citric AcidDasatinib may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe serum concentration of Dasatinib can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Dasatinib can be decreased when combined with Clemastine.Approved
ClindamycinThe serum concentration of Clindamycin can be increased when it is combined with Dasatinib.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Dasatinib.Approved, Illicit
ClofazimineThe serum concentration of Clofazimine can be increased when it is combined with Dasatinib.Approved, Investigational
ClofibrateThe serum concentration of Clofibrate can be increased when it is combined with Dasatinib.Approved
clomethiazoleThe serum concentration of clomethiazole can be increased when it is combined with Dasatinib.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Dasatinib.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Dasatinib.Approved, Vet Approved
ClonazepamThe serum concentration of Clonazepam can be increased when it is combined with Dasatinib.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Dasatinib.Approved
ClopidogrelDasatinib may increase the anticoagulant activities of Clopidogrel.Approved, Nutraceutical
ClorazepateThe serum concentration of Clorazepate can be increased when it is combined with Dasatinib.Approved, Illicit
ClotiazepamThe serum concentration of Clotiazepam can be increased when it is combined with Dasatinib.Approved, Illicit
ClotrimazoleThe metabolism of Dasatinib can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Dasatinib is combined with Clozapine.Approved
CobicistatThe serum concentration of Dasatinib can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Dasatinib.Approved
CocaineThe serum concentration of Cocaine can be increased when it is combined with Dasatinib.Approved, Illicit
CodeineThe serum concentration of Codeine can be increased when it is combined with Dasatinib.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Dasatinib.Approved
ColforsinThe serum concentration of Dasatinib can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Dasatinib can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Dasatinib.Approved
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Dasatinib.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Dasatinib.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Dasatinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Dasatinib.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Dasatinib.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Dasatinib can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Dasatinib.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dasatinib.Approved
DabrafenibThe serum concentration of Dasatinib can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Dasatinib.Approved
DactinomycinThe serum concentration of Dasatinib can be increased when it is combined with Dactinomycin.Approved
DalteparinDasatinib may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidDasatinib may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DantroleneThe serum concentration of Dantrolene can be increased when it is combined with Dasatinib.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Dasatinib.Approved
DapsoneThe serum concentration of Dapsone can be increased when it is combined with Dasatinib.Approved, Investigational
DarexabanDasatinib may increase the anticoagulant activities of Ym150.Investigational
DarifenacinThe serum concentration of Darifenacin can be increased when it is combined with Dasatinib.Approved, Investigational
DarunavirThe serum concentration of Dasatinib can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Dasatinib.Approved
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Dasatinib.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Dasatinib.Approved
DeferasiroxThe serum concentration of Dasatinib can be decreased when it is combined with Deferasirox.Approved, Investigational
DefibrotideDasatinib may increase the anticoagulant activities of Defibrotide.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be increased when it is combined with Dasatinib.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Dasatinib.Approved
DesipramineThe serum concentration of Dasatinib can be increased when it is combined with Desipramine.Approved
DesirudinDasatinib may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Dasatinib.Approved
DesloratadineThe serum concentration of Dasatinib can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe serum concentration of Desvenlafaxine can be increased when it is combined with Dasatinib.Approved
DexamethasoneThe serum concentration of Dasatinib can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Dasatinib.Approved, Investigational, Vet Approved
DexlansoprazoleThe serum concentration of Dasatinib can be decreased when it is combined with TAK-390MR.Approved
DextranDasatinib may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Dasatinib may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Dasatinib may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Dasatinib may increase the anticoagulant activities of Dextran 75.Approved
DextromethorphanThe serum concentration of Dextromethorphan can be increased when it is combined with Dasatinib.Approved
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be increased when it is combined with Dasatinib.Approved, Illicit, Withdrawn
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Dasatinib.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Dasatinib.Approved, Vet Approved
DicoumarolDasatinib may increase the anticoagulant activities of Dicoumarol.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Dasatinib.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Dasatinib.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Dasatinib.Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be increased when it is combined with Dasatinib.Approved, Illicit
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Dasatinib.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Dasatinib.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Dasatinib.Approved
DipyridamoleDasatinib may increase the anticoagulant activities of Dipyridamole.Approved
DisopyramideThe serum concentration of Disopyramide can be increased when it is combined with Dasatinib.Approved
DisulfiramThe serum concentration of Disulfiram can be increased when it is combined with Dasatinib.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Dasatinib.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Dasatinib.Approved
DolasetronThe serum concentration of Dolasetron can be increased when it is combined with Dasatinib.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Dasatinib.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be increased when it is combined with Dasatinib.Approved
DorzolamideThe serum concentration of Dorzolamide can be increased when it is combined with Dasatinib.Approved
DoxazosinThe serum concentration of Dasatinib can be increased when it is combined with Doxazosin.Approved
DoxepinDoxepin can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Dasatinib.Approved, Investigational
DoxycyclineThe metabolism of Dasatinib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Dasatinib.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Dasatinib.Approved
DroperidolDasatinib may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Dasatinib.Approved, Investigational
Edetic AcidDasatinib may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Dasatinib.Approved
EfavirenzThe serum concentration of Efavirenz can be increased when it is combined with Dasatinib.Approved, Investigational
ElbasvirThe serum concentration of Dasatinib can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Dasatinib.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Dasatinib.Approved
EltrombopagThe serum concentration of Dasatinib can be increased when it is combined with Eltrombopag.Approved
ElvitegravirThe serum concentration of Elvitegravir can be increased when it is combined with Dasatinib.Approved
EnalaprilThe serum concentration of Enalapril can be increased when it is combined with Dasatinib.Approved, Vet Approved
EnoxaparinDasatinib may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Dasatinib can be decreased when it is combined with Enzalutamide.Approved
EpinastineEpinastine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Dasatinib.Approved
eplivanserineDasatinib may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolDasatinib may increase the anticoagulant activities of Epoprostenol.Approved
EptifibatideDasatinib may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
ErgocalciferolThe serum concentration of Ergocalciferol can be increased when it is combined with Dasatinib.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Dasatinib.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Dasatinib.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Dasatinib.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Dasatinib.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Dasatinib.Approved, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be increased when it is combined with Dasatinib.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Dasatinib can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe serum concentration of Dasatinib can be decreased when it is combined with Esomeprazole.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Dasatinib.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Dasatinib.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be increased when it is combined with Dasatinib.Approved
EstramustineThe serum concentration of Estramustine can be increased when it is combined with Dasatinib.Approved
EstriolThe serum concentration of Dasatinib can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Dasatinib.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Dasatinib.Approved
EszopicloneThe serum concentration of Eszopiclone can be increased when it is combined with Dasatinib.Approved
EthanolThe serum concentration of Ethanol can be increased when it is combined with Dasatinib.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Dasatinib.Approved
EthosuximideThe serum concentration of Ethosuximide can be increased when it is combined with Dasatinib.Approved
Ethyl biscoumacetateDasatinib may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthylmorphineThe serum concentration of Ethylmorphine can be increased when it is combined with Dasatinib.Approved, Illicit
EtonogestrelThe serum concentration of Etonogestrel can be increased when it is combined with Dasatinib.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Dasatinib.Approved
EtoricoxibThe serum concentration of Etoricoxib can be increased when it is combined with Dasatinib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Dasatinib.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Dasatinib.Approved
ExemestaneThe serum concentration of Exemestane can be increased when it is combined with Dasatinib.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Dasatinib.Approved
FamciclovirThe serum concentration of Famciclovir can be increased when it is combined with Dasatinib.Approved
FamotidineFamotidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FelbamateThe serum concentration of Felbamate can be increased when it is combined with Dasatinib.Approved
FelodipineThe serum concentration of Felodipine can be increased when it is combined with Dasatinib.Approved, Investigational
FenofibrateThe serum concentration of Fenofibrate can be increased when it is combined with Dasatinib.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Dasatinib.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Dasatinib.Approved
FexofenadineThe serum concentration of Dasatinib can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Dasatinib.Approved
FinasterideThe serum concentration of Finasteride can be increased when it is combined with Dasatinib.Approved
FingolimodDasatinib may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlecainideDasatinib may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Dasatinib.Approved
FluconazoleThe metabolism of Dasatinib can be decreased when combined with Fluconazole.Approved
FluindioneDasatinib may increase the anticoagulant activities of Fluindione.Investigational
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Dasatinib.Approved, Investigational
FlunitrazepamThe serum concentration of Flunitrazepam can be increased when it is combined with Dasatinib.Approved, Illicit
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Dasatinib.Approved
FluoxetineThe serum concentration of Fluoxetine can be increased when it is combined with Dasatinib.Approved, Vet Approved
FlupentixolDasatinib may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Dasatinib can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Flurazepam can be increased when it is combined with Dasatinib.Approved, Illicit
FlutamideThe serum concentration of Flutamide can be increased when it is combined with Dasatinib.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Dasatinib.Approved
Fluticasone propionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Dasatinib.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Dasatinib.Approved
FluvoxamineThe metabolism of Dasatinib can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxDasatinib may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumDasatinib may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be increased when it is combined with Dasatinib.Approved
FosaprepitantThe serum concentration of Dasatinib can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Dasatinib can be decreased when it is combined with Fosphenytoin.Approved
FulvestrantThe serum concentration of Fulvestrant can be increased when it is combined with Dasatinib.Approved, Investigational
Fusidic AcidThe serum concentration of Dasatinib can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Dasatinib is combined with G17DT.Investigational
GabexateDasatinib may increase the anticoagulant activities of Gabexate.Investigational
Gadobenic acidDasatinib may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineThe serum concentration of Galantamine can be increased when it is combined with Dasatinib.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Dasatinib.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Dasatinib.Approved
GemfibrozilThe serum concentration of Gemfibrozil can be increased when it is combined with Dasatinib.Approved
GemifloxacinDasatinib may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Dasatinib can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Dasatinib is combined with GI-5005.Investigational
GlipizideThe serum concentration of Glipizide can be increased when it is combined with Dasatinib.Approved
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Dasatinib.Approved
GoserelinDasatinib may increase the QTc-prolonging activities of Goserelin.Approved
Gramicidin DThe serum concentration of Dasatinib can be increased when it is combined with Gramicidin D.Approved
GranisetronThe serum concentration of Granisetron can be increased when it is combined with Dasatinib.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Dasatinib.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Dasatinib.Withdrawn
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Dasatinib.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Dasatinib.Approved
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Dasatinib.Approved
HalothaneThe serum concentration of Halothane can be increased when it is combined with Dasatinib.Approved, Vet Approved
HeparinDasatinib may increase the anticoagulant activities of Heparin.Approved, Investigational
HexobarbitalThe serum concentration of Hexobarbital can be increased when it is combined with Dasatinib.Approved
HistamineThe serum concentration of Histamine Phosphate can be increased when it is combined with Dasatinib.Approved, Investigational
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Dasatinib.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Dasatinib.Approved, Vet Approved
HydromorphoneThe serum concentration of Hydromorphone can be increased when it is combined with Dasatinib.Approved, Illicit
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be increased when it is combined with Dasatinib.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Dasatinib.Approved
IbudilastDasatinib may increase the anticoagulant activities of Ibudilast.Approved, Investigational
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Dasatinib.Approved
IbutilideDasatinib may increase the QTc-prolonging activities of Ibutilide.Approved
Icosapent ethylDasatinib may increase the anticoagulant activities of Icosapent ethyl.Approved, Nutraceutical
IdelalisibThe serum concentration of Dasatinib can be increased when it is combined with Idelalisib.Approved
IdraparinuxDasatinib may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilDasatinib may increase the anticoagulant activities of Ifenprodil.Approved, Withdrawn
IfosfamideThe serum concentration of Ifosfamide can be increased when it is combined with Dasatinib.Approved
IloperidoneThe serum concentration of Iloperidone can be increased when it is combined with Dasatinib.Approved
IloprostDasatinib may increase the anticoagulant activities of Iloprost.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Dasatinib.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Dasatinib.Approved
ImiquimodThe serum concentration of Imiquimod can be increased when it is combined with Dasatinib.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Dasatinib.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Dasatinib.Approved
IndinavirThe serum concentration of Dasatinib can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Dasatinib can be increased when it is combined with Indomethacin.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Dasatinib is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Dasatinib is combined with INGN 225.Investigational
Ipratropium bromideThe serum concentration of Ipratropium bromide can be increased when it is combined with Dasatinib.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Dasatinib.Approved, Investigational
IsavuconazoniumThe serum concentration of Isavuconazonium can be increased when it is combined with Dasatinib.Approved, Investigational
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Dasatinib.Approved
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Dasatinib.Approved
IsradipineThe serum concentration of Isradipine can be increased when it is combined with Dasatinib.Approved
ItraconazoleThe serum concentration of Dasatinib can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Dasatinib.Approved
IvacaftorThe serum concentration of Dasatinib can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Dasatinib.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Dasatinib.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be increased when it is combined with Dasatinib.Approved
KetamineThe serum concentration of Ketamine can be increased when it is combined with Dasatinib.Approved, Vet Approved
KetanserinDasatinib may increase the anticoagulant activities of Ketanserin.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Dasatinib.Approved
KetobemidoneThe serum concentration of Ketobemidone can be increased when it is combined with Dasatinib.Approved
KetoconazoleThe serum concentration of Dasatinib can be increased when it is combined with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Dasatinib.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Dasatinib.Approved, Investigational
LansoprazoleThe serum concentration of Dasatinib can be decreased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Dasatinib.Approved, Investigational
LaquinimodThe serum concentration of Laquinimod can be increased when it is combined with Dasatinib.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Dasatinib.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Dasatinib is combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Dasatinib.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Dasatinib.Approved
LepirudinDasatinib may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Dasatinib.Approved, Investigational
LetrozoleThe serum concentration of Letrozole can be increased when it is combined with Dasatinib.Approved, Investigational
LeuprolideDasatinib may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Dasatinib.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Dasatinib.Approved
LevocetirizineThe serum concentration of Levocetirizine can be increased when it is combined with Dasatinib.Approved
LevofloxacinDasatinib may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Dasatinib.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Dasatinib.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be increased when it is combined with Dasatinib.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be increased when it is combined with Dasatinib.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Dasatinib.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Dasatinib.Approved
LiothyronineThe serum concentration of Dasatinib can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Dasatinib can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Dasatinib can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe serum concentration of Lisuride can be increased when it is combined with Dasatinib.Approved
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Dasatinib.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Dasatinib.Approved
LopinavirThe serum concentration of Dasatinib can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Loratadine can be increased when it is combined with Dasatinib.Approved
LorcaserinThe serum concentration of Lorcaserin can be increased when it is combined with Dasatinib.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Dasatinib.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Dasatinib.Approved, Investigational
LuliconazoleThe serum concentration of Dasatinib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Dasatinib can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Dasatinib.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Dasatinib.Approved
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Dasatinib.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium HydroxideMagnesium hydroxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Dasatinib.Approved, Investigational
MaprotilineThe serum concentration of Dasatinib can be increased when it is combined with Maprotiline.Approved
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Dasatinib.Approved, Investigational
MebendazoleThe serum concentration of Mebendazole can be increased when it is combined with Dasatinib.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Dasatinib.Approved, Investigational
MefloquineThe serum concentration of Mefloquine can be increased when it is combined with Dasatinib.Approved
Megestrol acetateThe serum concentration of Dasatinib can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeloxicamThe serum concentration of Meloxicam can be increased when it is combined with Dasatinib.Approved, Vet Approved
MeprobamateThe serum concentration of Dasatinib can be increased when it is combined with Meprobamate.Approved, Illicit
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Dasatinib.Withdrawn
MethadoneThe serum concentration of Methadone can be increased when it is combined with Dasatinib.Approved
MethanthelineMethantheline can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethaqualoneThe serum concentration of Methaqualone can be increased when it is combined with Dasatinib.Illicit, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Dasatinib.Approved
MethoxsalenThe serum concentration of Methoxsalen can be increased when it is combined with Dasatinib.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be increased when it is combined with Dasatinib.Approved, Vet Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Dasatinib.Approved, Vet Approved
MethyltestosteroneThe serum concentration of Methyltestosterone can be increased when it is combined with Dasatinib.Approved
MetiamideMetiamide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
MetoprololThe serum concentration of Dasatinib can be increased when it is combined with Metoprolol.Approved, Investigational
MetronidazoleThe serum concentration of Metronidazole can be increased when it is combined with Dasatinib.Approved
MexiletineThe serum concentration of Mexiletine can be increased when it is combined with Dasatinib.Approved
MianserinThe serum concentration of Mianserin can be increased when it is combined with Dasatinib.Approved
MibefradilThe serum concentration of Mibefradil can be increased when it is combined with Dasatinib.Withdrawn
MiconazoleThe serum concentration of Miconazole can be increased when it is combined with Dasatinib.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Dasatinib.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Dasatinib.Approved, Investigational
MilrinoneDasatinib may increase the anticoagulant activities of Milrinone.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Dasatinib.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Dasatinib.Approved
MitomycinThe serum concentration of Dasatinib can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Dasatinib can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Dasatinib can be decreased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Modafinil can be increased when it is combined with Dasatinib.Approved, Investigational
MontelukastThe serum concentration of Montelukast can be increased when it is combined with Dasatinib.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Dasatinib.Approved, Investigational
MoxifloxacinDasatinib may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Dasatinib.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Dasatinib.Approved
NadroparinDasatinib may increase the anticoagulant activities of Nadroparin.Approved
NafamostatDasatinib may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NafcillinThe serum concentration of Dasatinib can be decreased when it is combined with Nafcillin.Approved
NaftopidilDasatinib may increase the anticoagulant activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Dasatinib.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Dasatinib.Approved, Vet Approved
NaltrexoneThe serum concentration of Dasatinib can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Dasatinib can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Dasatinib is combined with Natalizumab.Approved, Investigational
NateglinideThe serum concentration of Nateglinide can be increased when it is combined with Dasatinib.Approved, Investigational
NefazodoneThe serum concentration of Dasatinib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Dasatinib can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Dasatinib can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Dasatinib can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Dasatinib can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Dasatinib.Approved
NicotineThe serum concentration of Nicotine can be increased when it is combined with Dasatinib.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Dasatinib.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Dasatinib.Approved, Investigational
NilvadipineThe serum concentration of Nilvadipine can be increased when it is combined with Dasatinib.Approved
NimesulideDasatinib may increase the anticoagulant activities of Nimesulide.Approved, Withdrawn
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Dasatinib.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Dasatinib.Approved
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Dasatinib.Approved
NitrazepamThe serum concentration of Nitrazepam can be increased when it is combined with Dasatinib.Approved
NitrendipineThe serum concentration of Nitrendipine can be increased when it is combined with Dasatinib.Approved
NitroaspirinDasatinib may increase the anticoagulant activities of Nitroaspirin.Investigational
NizatidineNizatidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NorethisteroneThe serum concentration of Norethisterone can be increased when it is combined with Dasatinib.Approved
NorgestrelThe serum concentration of Norgestrel can be increased when it is combined with Dasatinib.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Dasatinib.Approved
OfloxacinDasatinib may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Dasatinib.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Dasatinib.Experimental
OlopatadineThe serum concentration of Olopatadine can be increased when it is combined with Dasatinib.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Dasatinib.Approved
OmeprazoleThe serum concentration of Dasatinib can be decreased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Dasatinib.Approved
OrphenadrineThe serum concentration of Orphenadrine can be increased when it is combined with Dasatinib.Approved
OsimertinibThe serum concentration of Dasatinib can be increased when it is combined with Osimertinib.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Dasatinib.Approved
OtamixabanDasatinib may increase the anticoagulant activities of Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Dasatinib.Approved
OxazepamThe serum concentration of Oxazepam can be increased when it is combined with Dasatinib.Approved
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Dasatinib.Approved, Investigational
OxycodoneThe serum concentration of Oxycodone can be increased when it is combined with Dasatinib.Approved, Illicit, Investigational
OxymorphoneThe serum concentration of Oxymorphone can be increased when it is combined with Dasatinib.Approved, Investigational, Vet Approved
P-NitrophenolThe serum concentration of Dasatinib can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Dasatinib.Approved, Vet Approved
PalbociclibThe serum concentration of Dasatinib can be increased when it is combined with Palbociclib.Approved
PaliperidoneDasatinib may increase the QTc-prolonging activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Dasatinib can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronThe serum concentration of Palonosetron can be increased when it is combined with Dasatinib.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Dasatinib.Approved, Investigational
PantoprazoleThe serum concentration of Dasatinib can be decreased when it is combined with Pantoprazole.Approved
ParamethadioneThe serum concentration of Paramethadione can be increased when it is combined with Dasatinib.Approved
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Dasatinib.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Dasatinib.Approved
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Dasatinib.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Dasatinib.Approved
ParoxetineThe serum concentration of Dasatinib can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Dasatinib.Approved
Peginterferon alfa-2bThe serum concentration of Dasatinib can be increased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThe serum concentration of Pentamidine can be increased when it is combined with Dasatinib.Approved
PentobarbitalThe serum concentration of Dasatinib can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateDasatinib may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineDasatinib may increase the anticoagulant activities of Pentoxifylline.Approved, Investigational
PerampanelThe serum concentration of Perampanel can be increased when it is combined with Dasatinib.Approved
PerflutrenDasatinib may increase the QTc-prolonging activities of Perflutren.Approved
PergolideThe serum concentration of Pergolide can be increased when it is combined with Dasatinib.Approved, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Perhexiline can be increased when it is combined with Dasatinib.Approved
PerindoprilThe serum concentration of Dasatinib can be increased when it is combined with Perindopril.Approved
PermethrinThe serum concentration of Permethrin can be increased when it is combined with Dasatinib.Approved, Investigational
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Dasatinib.Approved
PethidineThe serum concentration of Pethidine can be increased when it is combined with Dasatinib.Approved
PhenacetinThe serum concentration of Phenacetin can be increased when it is combined with Dasatinib.Withdrawn
PhenindioneDasatinib may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe serum concentration of Dasatinib can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be increased when it is combined with Dasatinib.Approved
PhenprocoumonDasatinib may increase the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe serum concentration of Dasatinib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe serum concentration of Pilocarpine can be increased when it is combined with Dasatinib.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dasatinib.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Dasatinib.Approved
PinacidilThe serum concentration of Pinacidil can be increased when it is combined with Dasatinib.Withdrawn
PioglitazoneThe serum concentration of Pioglitazone can be increased when it is combined with Dasatinib.Approved, Investigational
PipotiazineThe serum concentration of Pipotiazine can be increased when it is combined with Dasatinib.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Dasatinib.Approved
Platelet Activating FactorThe serum concentration of Dasatinib can be decreased when it is combined with Platelet Activating Factor.Experimental
PodofiloxThe serum concentration of Podofilox can be increased when it is combined with Dasatinib.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Dasatinib.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Dasatinib.Approved
PosaconazoleThe serum concentration of Dasatinib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrasteroneThe serum concentration of Prasterone can be increased when it is combined with Dasatinib.Approved, Nutraceutical
PrasugrelDasatinib may increase the anticoagulant activities of Prasugrel.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Dasatinib.Approved
PrazepamThe serum concentration of Prazepam can be increased when it is combined with Dasatinib.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be increased when it is combined with Dasatinib.Approved, Vet Approved
PrazosinThe serum concentration of Dasatinib can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Dasatinib.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Dasatinib.Approved, Vet Approved
PrimaquineThe serum concentration of Primaquine can be increased when it is combined with Dasatinib.Approved
PrimidoneThe serum concentration of Dasatinib can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Dasatinib can be increased when it is combined with Probenecid.Approved
ProcainamideDasatinib may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Dasatinib.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Dasatinib.Approved, Vet Approved
ProguanilThe serum concentration of Proguanil can be increased when it is combined with Dasatinib.Approved
PromazineThe serum concentration of Promazine can be increased when it is combined with Dasatinib.Approved, Vet Approved
PromethazineThe serum concentration of Dasatinib can be increased when it is combined with Promethazine.Approved
PropacetamolDasatinib may increase the hepatotoxic activities of Propacetamol.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Dasatinib.Approved
PropofolThe serum concentration of Propofol can be increased when it is combined with Dasatinib.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Dasatinib.Approved, Investigational
Protein CDasatinib may increase the anticoagulant activities of Protein C.Approved
Protein S humanDasatinib may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeDasatinib may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe serum concentration of Dasatinib can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Dasatinib.Approved
PyrazinamideThe serum concentration of Pyrazinamide can be increased when it is combined with Dasatinib.Approved
QuazepamThe serum concentration of Quazepam can be increased when it is combined with Dasatinib.Approved, Illicit
QuercetinThe serum concentration of Dasatinib can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Dasatinib.Approved
QuinacrineThe serum concentration of Quinacrine can be increased when it is combined with Dasatinib.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Dasatinib.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Dasatinib.Approved
RabeprazoleThe serum concentration of Dasatinib can be decreased when it is combined with Rabeprazole.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Dasatinib is combined with Rabies vaccine.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Dasatinib.Approved
RaloxifeneThe serum concentration of Raloxifene can be increased when it is combined with Dasatinib.Approved, Investigational
RamatrobanDasatinib may increase the anticoagulant activities of Ramatroban.Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Dasatinib.Approved, Investigational
RanitidineRanitidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Dasatinib.Approved, Investigational
ReboxetineThe serum concentration of Reboxetine can be increased when it is combined with Dasatinib.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Dasatinib.Approved
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Dasatinib.Approved, Investigational
ReserpineThe serum concentration of Dasatinib can be decreased when it is combined with Reserpine.Approved
ResveratrolDasatinib may increase the anticoagulant activities of Resveratrol.Experimental, Investigational
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Dasatinib.Approved
ReviparinDasatinib may increase the anticoagulant activities of Reviparin.Approved
RidogrelDasatinib may increase the anticoagulant activities of Ridogrel.Approved
RifabutinThe serum concentration of Dasatinib can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Dasatinib can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Dasatinib can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Dasatinib.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Dasatinib.Approved
RimonabantThe serum concentration of Rimonabant can be increased when it is combined with Dasatinib.Approved, Investigational
RindopepimutThe risk or severity of adverse effects can be increased when Dasatinib is combined with CDX-110.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Dasatinib.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Dasatinib.Approved, Investigational
RitonavirThe serum concentration of Dasatinib can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanDasatinib may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe serum concentration of Rofecoxib can be increased when it is combined with Dasatinib.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Dasatinib.Approved
RolapitantThe serum concentration of Dasatinib can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Dasatinib.Approved, Investigational
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Dasatinib.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Dasatinib.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Dasatinib.Approved
RotigotineThe serum concentration of Rotigotine can be increased when it is combined with Dasatinib.Approved
Roxatidine acetateRoxatidine acetate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RoxithromycinThe serum concentration of Roxithromycin can be increased when it is combined with Dasatinib.Approved, Withdrawn
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Dasatinib.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Dasatinib.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Dasatinib.Approved
SaquinavirThe serum concentration of Dasatinib can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Dasatinib.Approved
ScopolamineThe serum concentration of Dasatinib can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Dasatinib.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Dasatinib.Approved
SeratrodastThe serum concentration of Seratrodast can be increased when it is combined with Dasatinib.Approved
SertindoleThe serum concentration of Sertindole can be increased when it is combined with Dasatinib.Approved, Withdrawn
SertralineThe serum concentration of Sertraline can be increased when it is combined with Dasatinib.Approved
SevofluraneDasatinib may increase the anticoagulant activities of Sevoflurane.Approved, Vet Approved
SibutramineThe serum concentration of Sibutramine can be increased when it is combined with Dasatinib.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Dasatinib.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Dasatinib.Approved
SiltuximabThe serum concentration of Dasatinib can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Dasatinib can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Dasatinib.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dasatinib.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Dasatinib.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Dasatinib.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Dasatinib.Approved
SolifenacinThe serum concentration of Solifenacin can be increased when it is combined with Dasatinib.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Dasatinib.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Dasatinib.Approved, Investigational
SotalolDasatinib may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Dasatinib.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Dasatinib.Experimental
SpiramycinThe serum concentration of Spiramycin can be increased when it is combined with Dasatinib.Approved
SpironolactoneThe serum concentration of Dasatinib can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Dasatinib is combined with SRP 299.Investigational
SRT501Dasatinib may increase the anticoagulant activities of SRT501.Investigational
St. John's WortThe serum concentration of Dasatinib can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Dasatinib can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Dasatinib can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Dasatinib can be decreased when it is combined with Streptozocin.Approved
SufentanilThe serum concentration of Sufentanil can be increased when it is combined with Dasatinib.Approved, Investigational
SulfadiazineThe serum concentration of Sulfadiazine can be increased when it is combined with Dasatinib.Approved, Vet Approved
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be increased when it is combined with Dasatinib.Approved
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be increased when it is combined with Dasatinib.Approved
SulfisoxazoleDasatinib may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulodexideDasatinib may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SumatriptanThe serum concentration of Dasatinib can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Sunitinib can be increased when it is combined with Dasatinib.Approved, Investigational
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be increased when it is combined with Dasatinib.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Dasatinib.Approved
TacrineThe serum concentration of Dasatinib can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Dasatinib.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Dasatinib.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Dasatinib.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Dasatinib.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Dasatinib.Approved, Investigational
TasosartanThe serum concentration of Tasosartan can be increased when it is combined with Dasatinib.Approved
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be increased when it is combined with Dasatinib.Experimental
Taurocholic AcidThe serum concentration of Dasatinib can be increased when it is combined with Taurocholic Acid.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Dasatinib.Approved
TelaprevirThe serum concentration of Dasatinib can be increased when it is combined with Telaprevir.Withdrawn
TelavancinDasatinib may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe serum concentration of Dasatinib can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Dasatinib can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe serum concentration of Temazepam can be increased when it is combined with Dasatinib.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Dasatinib.Approved
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Dasatinib.Approved
Tenofovir disoproxilThe metabolism of Dasatinib can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe serum concentration of Dasatinib can be increased when it is combined with Terazosin.Approved
TerbinafineThe serum concentration of Terbinafine can be increased when it is combined with Dasatinib.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Dasatinib.Withdrawn
TeriflunomideThe serum concentration of Dasatinib can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneDasatinib may increase the anticoagulant activities of Tesmilifene.Investigational
TestosteroneThe serum concentration of Testosterone can be increased when it is combined with Dasatinib.Approved, Investigational
TetrabenazineDasatinib may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Dasatinib.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when Dasatinib is combined with TG4010.Investigational
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Dasatinib.Approved
ThioridazineDasatinib may increase the QTc-prolonging activities of Thioridazine.Withdrawn
ThiotepaThe serum concentration of Thiotepa can be increased when it is combined with Dasatinib.Approved
TiagabineThe serum concentration of Tiagabine can be increased when it is combined with Dasatinib.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Dasatinib.Approved
TiclopidineDasatinib may increase the anticoagulant activities of Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Dasatinib.Approved
TinidazoleThe serum concentration of Tinidazole can be increased when it is combined with Dasatinib.Approved, Investigational
TiotropiumThe serum concentration of Tiotropium can be increased when it is combined with Dasatinib.Approved
TipranavirThe serum concentration of Tipranavir can be increased when it is combined with Dasatinib.Approved, Investigational
TirofibanDasatinib may increase the anticoagulant activities of Tirofiban.Approved
TocilizumabThe serum concentration of Dasatinib can be decreased when it is combined with Tocilizumab.Approved
TofacitinibDasatinib may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Dasatinib.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Dasatinib.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Dasatinib.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Dasatinib.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Dasatinib.Approved, Investigational
TramadolThe serum concentration of Tramadol can be increased when it is combined with Dasatinib.Approved, Investigational
TranilastDasatinib may increase the anticoagulant activities of Tranilast.Approved, Investigational
TrapidilDasatinib may increase the anticoagulant activities of Trapidil.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Dasatinib.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Dasatinib.Approved
TrazodoneThe serum concentration of Trazodone can be increased when it is combined with Dasatinib.Approved, Investigational
TretinoinThe serum concentration of Tretinoin can be increased when it is combined with Dasatinib.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Dasatinib.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Dasatinib.Approved
TrifluoperazineThe serum concentration of Dasatinib can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Dasatinib can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TriflusalDasatinib may increase the anticoagulant activities of Triflusal.Approved
TrimethadioneThe serum concentration of Trimethadione can be increased when it is combined with Dasatinib.Approved
TrimethoprimThe serum concentration of Trimethoprim can be increased when it is combined with Dasatinib.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Dasatinib.Approved
TroglitazoneThe serum concentration of Troglitazone can be increased when it is combined with Dasatinib.Withdrawn
UdenafilThe serum concentration of Udenafil can be increased when it is combined with Dasatinib.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Dasatinib.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Dasatinib.Approved
ValdecoxibThe serum concentration of Valdecoxib can be increased when it is combined with Dasatinib.Investigational, Withdrawn
VandetanibThe serum concentration of Vandetanib can be increased when it is combined with Dasatinib.Approved
VanoxerineThe serum concentration of Vanoxerine can be increased when it is combined with Dasatinib.Investigational
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Dasatinib.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Dasatinib.Approved
VemurafenibThe serum concentration of Dasatinib can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Dasatinib.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Dasatinib.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Dasatinib.Approved
VicrivirocThe serum concentration of Vicriviroc can be increased when it is combined with Dasatinib.Investigational
VilanterolThe serum concentration of Vilanterol can be increased when it is combined with Dasatinib.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Dasatinib.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Dasatinib.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Dasatinib.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Dasatinib.Approved
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Dasatinib.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Dasatinib.Approved
VorapaxarDasatinib may increase the anticoagulant activities of Vorapaxar.Approved
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Dasatinib.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Dasatinib.Approved
WarfarinDasatinib may increase the anticoagulant activities of Warfarin.Approved
XimelagatranDasatinib may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Dasatinib.Approved, Vet Approved
ZafirlukastThe serum concentration of Zafirlukast can be increased when it is combined with Dasatinib.Approved, Investigational
ZalcitabineThe serum concentration of Zalcitabine can be increased when it is combined with Dasatinib.Approved
ZaleplonThe serum concentration of Zaleplon can be increased when it is combined with Dasatinib.Approved, Illicit, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Dasatinib.Approved
ZileutonThe serum concentration of Zileuton can be increased when it is combined with Dasatinib.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Dasatinib can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Ziprasidone can be increased when it is combined with Dasatinib.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Dasatinib.Approved
ZomepiracThe serum concentration of Zomepirac can be increased when it is combined with Dasatinib.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be increased when it is combined with Dasatinib.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Dasatinib.Approved
ZuclopenthixolDasatinib may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceUS6596746
General References
  1. Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC: 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem. 2006 Nov 16;49(23):6819-32. [PubMed:17154512 ]
  2. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 Jun 15;354(24):2531-41. [PubMed:16775234 ]
External Links
ATC CodesL01XE06 — Dasatinib
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (237 KB)
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceEndometrial Cancers1
0TerminatedBasic ScienceHepatic Metastases / Mucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IV Colon Cancer / Stage IV Rectal Cancer1
1Active Not RecruitingTreatmentAdvanced Cancers1
1Active Not RecruitingTreatmentCancer, Advanced1
1Active Not RecruitingTreatmentChronic Myeloid Leukemia (CML)1
1Active Not RecruitingTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Mucinous Adenocarcinoma / Endometrial Serous Adenocarcinoma / Endometrial Transitional Cell Carcinoma / Endometrial Undifferentiated Carcinoma / Endometrioid Adenocarcinoma / Recurrent Uterine Corpus Carcinoma / Stage III Uterine Corpus Cancer / Stage IIIA Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IV Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer / Uterine Carcinosarcoma1
1Active Not RecruitingTreatmentLeukemias1
1Active Not RecruitingTreatmentLung Cancers / Non-Small-Cell Lung Carcinoma (NSCLC)1
1Active Not RecruitingTreatmentMalignant Pleural Mesothelioma (MPM)1
1Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic / Recurrent Pancreatic Carcinoma / Stage III Pancreatic Cancer / Stage III Pancreatic Cancer AJCC v6 and v7 / Stage IV Pancreatic Cancer / Stage IV Pancreatic Cancer AJCC v6 and v71
1Active Not RecruitingTreatmentTumors, Solid1
1CompletedNot AvailablePharmacokinetic Study in Healthy Participants1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedSupportive CareHealthy Volunteers1
1CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Childhood Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Meningeal Chronic Myelogenous Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Relapsing Chronic Myelogenous Leukemia / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
1CompletedTreatmentAcute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome1
1CompletedTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia / Adult Hepatocellular Carcinoma / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Solid Neoplasm / Adult T Acute Lymphoblastic Leukemia / Advanced Adult Hepatocellular Carcinoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Localized Non-Resectable Adult Liver Carcinoma / Localized Resectable Adult Liver Carcinoma / Lymphomatous Involvement of Non-Cutaneous Extranodal Site / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Nodal Marginal Zone Lymphoma / Progressive Hairy Cell Leukemia Initial Treatment / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Lymphoma / Recurrent Adult Liver Carcinoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides and Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Small Intestinal Lymphoma / Splenic Marginal Zone Lymphoma / Stage II Small Lymphocytic Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IIIA Mycosis Fungoides and Sezary Syndrome / Stage IIIB Mycosis Fungoides and Sezary Syndrome / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Stage IVA Mycosis Fungoides and Sezary Syndrome / Stage IVB Mycosis Fungoides and Sezary Syndrome / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Hairy Cell Leukemia / Waldenstrom's Macroglobulinemia (WM)1
1CompletedTreatmentAdvanced Breast Cancer1
1CompletedTreatmentCancer, Advanced1
1CompletedTreatmentCancer, Advanced / Tumors, Solid1
1CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cancer1
1CompletedTreatmentColorectal Cancers1
1CompletedTreatmentDiffuse Intrinsic Pontine Glioma (DIPG)1
1CompletedTreatmentGastrointestinal Stromal Tumors / Stage III Soft Tissue Sarcoma / Stage IV Soft Tissue Sarcoma1
1CompletedTreatmentGlioblastomas / Gliosarcoma1
1CompletedTreatmentHead and Neck Carcinoma / Non-Small-Cell Lung Carcinoma (NSCLC)1
1CompletedTreatmentLeukemia, Lymphoblastic, Acute, Philadelphia-Positive / Leukemia, Myeloid, Chronic-Phase1
1CompletedTreatmentLeukemias4
1CompletedTreatmentMalignant Solid Tumours1
1CompletedTreatmentMetastatic Colorectal Cancers / Tumors, Solid1
1CompletedTreatmentMultiple Myeloma (MM)1
1CompletedTreatmentNeoplasms1
1CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1CompletedTreatmentTumors1
1CompletedTreatmentTumors, Solid2
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1RecruitingBasic ScienceIdiopathic Pulmonary Fibrosis (IPF)1
1RecruitingHealth Services ResearchChronic Myelogenous Leukemia (CML) / Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)2
1RecruitingTreatmentAcute Myeloid Leukaemias (AML)1
1RecruitingTreatmentB Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Refractory Adult Acute Lymphoblastic Leukemia / Refractory Childhood Acute Lymphoblastic Leukemia1
1RecruitingTreatmentDiffuse Intrinsic Pontine Glioma (DIPG) / High-Grade Gliomas1
1RecruitingTreatmentNeuroblastomas1
1RecruitingTreatmentTumors, Solid1
1RecruitingTreatmentUntreated Adult Acute Myeloid Leukemia1
1TerminatedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase Chronic Myelogenous Leukemia / Relapsing Chronic Myelogenous Leukemia1
1TerminatedTreatmentAdenocarcinoma of the Pancreas / Refractory Solid Tumors1
1TerminatedTreatmentBrain Diseases / CNS Disease / Glioblastomas1
1TerminatedTreatmentChronic Myelogenous Leukemia (CML)1
1TerminatedTreatmentChronic Myelogenous Leukemia (CML) / Leukemia, Lymphoblastic, Acute, Philadelphia-Positive1
1TerminatedTreatmentMultiple Myeloma (MM)1
1TerminatedTreatmentTumors1
1WithdrawnTreatmentChronic Lymphocytic Leukaemia (CLL)1
1WithdrawnTreatmentHealthy Volunteers1
1WithdrawnTreatmentProstate Cancer1
1, 2Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1, 2Active Not RecruitingTreatmentBone Metastases / Cancer, Breast1
1, 2Active Not RecruitingTreatmentBrain and Central Nervous System Tumors1
1, 2Active Not RecruitingTreatmentBrain and Central Nervous System Tumors / Cancer, Ovarian / Childhood Germ Cell Tumor / Extragonadal Germ Cell Tumor / Liver Cancer / Malignant Lymphomas / Neuroblastomas / Renal Cancers / Sarcomas / Testicular germ cell tumour / Unspecified Childhood Solid Tumor, Protocol Specific1
1, 2Active Not RecruitingTreatmentCancer, Breast1
1, 2Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1, 2CompletedTreatmentAcute Myeloid Leukaemias (AML)1
1, 2CompletedTreatmentChronic Myelocytic Leukemia1
1, 2CompletedTreatmentChronic Myelogenous Leukemia (CML)1
1, 2CompletedTreatmentChronic Myelogenous Leukemia (CML) / Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia1
1, 2CompletedTreatmentLeukemias1
1, 2CompletedTreatmentLung Cancers / Non-Small-Cell Lung Carcinoma (NSCLC)1
1, 2CompletedTreatmentMetastatic Breast Cancer (MBC)1
1, 2CompletedTreatmentMetastatic Hormone Refractory Prostate Cancer1
1, 2CompletedTreatmentMetastatic Melanoma1
1, 2CompletedTreatmentScleroderma1
1, 2Not Yet RecruitingTreatmentChronic Myelogenous Leukemia, Ph1-Positive1
1, 2RecruitingTreatmentEGFR Gene Mutations / Nonsmall Cell Lung Cancer1
1, 2RecruitingTreatmentLeukemia, Lymphocytic / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myeloid Leukemias / Non-Hodgkin's Lymphoma (NHL)1
1, 2RecruitingTreatmentLeukemias1
1, 2RecruitingTreatmentLymphoma, Hodgkins / Multiple / Multiple Myeloma (MM) / Mycosis Fungoides (MF) / Non-Hodgkin's Lymphoma (NHL)1
1, 2RecruitingTreatmentRhabdomyosarcoma- Alveolar / Rhabdomyosarcoma-Embryonal / Rhabdomyosarcomas1
1, 2TerminatedTreatmentCancer, Breast1
1, 2TerminatedTreatmentGlioblastomas1
1, 2TerminatedTreatmentHead and Neck Carcinoma1
1, 2Unknown StatusTreatmentChronic Lymphocytic Leukaemia (CLL)1
1, 2Unknown StatusTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias1
2Active Not RecruitingNot AvailableChronic Phase of Chronic Myeloid Leukemia1
2Active Not RecruitingOtherChronic Phase Chronic Myeloid Leukemia1
2Active Not RecruitingSupportive CareMultiple Indications Cancer1
2Active Not RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2Active Not RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Adult L1 Acute Lymphoblastic Leukemia / Adult L2 Acute Lymphoblastic Leukemia / Adult T Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase Chronic Myelogenous Leukemia / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Relapsing Chronic Myelogenous Leukemia1
2Active Not RecruitingTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Neoplasm1
2Active Not RecruitingTreatmentAlveolar Soft Part Sarcoma (ASPS) / Chondrosarcomas / Chordomas / Epithelioid Sarcoma / Ewing's Sarcoma (ES) / Gastrointestinal Stromal Tumors (GISTs) / Giant Cell Tumors of Bone / Hemangiopericytoma / Malignant Peripheral Nerve Sheath Tumour (MPNST) / Rhabdomyosarcomas1
2Active Not RecruitingTreatmentCholangiocarcinomas1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Refractory Chronic Lymphocytic Leukemia / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia1
2Active Not RecruitingTreatmentChronic Myelogenous Leukemia (CML)1
2Active Not RecruitingTreatmentChronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase of Disease1
2Active Not RecruitingTreatmentChronic Myeloid Leukemia (CML)2
2Active Not RecruitingTreatmentChronic Phase Chronic Myeloid Leukemia1
2Active Not RecruitingTreatmentEndometrial Clear Cell Adenocarcinoma / Estrogen Receptor Negative / Ovarian Clear Cell Cystadenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Recurrent Uterine Corpus Carcinoma1
2Active Not RecruitingTreatmentGastrointestinal Stromal Tumors1
2Active Not RecruitingTreatmentGlioblastoma Multiforme1
2Active Not RecruitingTreatmentHigh-grade Salivary Gland Mucoepidermoid Carcinoma / Low-grade Salivary Gland Mucoepidermoid Carcinoma / Recurrent Salivary Gland Cancer / Salivary Gland Acinic Cell Tumor / Salivary Gland Adenocarcinoma / Salivary Gland Adenoid Cystic Carcinoma / Salivary Gland Anaplastic Carcinoma / Salivary Gland Malignant Mixed Cell Type Tumor / Salivary Gland Poorly Differentiated Carcinoma / Salivary Gland Squamous Cell Carcinoma / Stage IV Salivary Gland Cancer1
2Active Not RecruitingTreatmentHormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
2Active Not RecruitingTreatmentLeukemia, Lymphoblastic, Acute, Philadelphia-Positive1
2Active Not RecruitingTreatmentLeukemias2
2Active Not RecruitingTreatmentMetastatic Cancers1
2Active Not RecruitingTreatmentPancreatic Cancer Metastatic1
2Active Not RecruitingTreatmentPediatric Leukemia1
2Active Not RecruitingTreatmentProstate Cancer1
2CompletedSupportive CareAcute Myelogenous Leukaemia (AML)1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2CompletedTreatmentAcute Myeloid Leukaemias (AML) / Agnogenic Myeloid Metaplasia / Hypereosinophilic Syndromes / Leukemia, Myelomonocytic, Chronic / Myelodysplastic Syndromes / Polycythemia Vera (PV) / Urticaria Pigmentosa1
2CompletedTreatmentAdenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage IV Pancreatic Cancer1
2CompletedTreatmentAdenocarcinoma of the Prostate / Hormone-Refractory Prostate Cancer / Hormone-Resistant Prostate Cancer / Prostate Cancer / Recurrent Prostate Cancer1
2CompletedTreatmentAdvanced Breast Cancer2
2CompletedTreatmentBlast Crisis / Chronic Myeloid Leukemia (CML)1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentCancer, Breast / Metastasis2
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL)1
2CompletedTreatmentChronic Myelogenous Leukemia (CML)1
2CompletedTreatmentChronic Myelogenous Leukemia, BCR/ABL Positive1
2CompletedTreatmentChronic Myeloid Leukemia (CML)3
2CompletedTreatmentChronic Myeloid Leukemia (CML) / Leukemia, Lymphoblastic, Acute, Philadelphia-Positive1
2CompletedTreatmentChronic Myeloid Leukemia (CML) / Philadelphia-Positive Myeloid Leukemia2
2CompletedTreatmentExtensive Stage Small Cell Lung Cancer / Limited Stage Small Cell Lung Cancer / Recurrent Small Cell Lung Cancer1
2CompletedTreatmentLeukemia, Lymphoblastic, Acute1
2CompletedTreatmentLeukemia, Lymphocytic, Acute, L2 / Leukemia,Myeloid, Chronic1
2CompletedTreatmentLeukemia, Myeloid, Chronic-Phase1
2CompletedTreatmentLeukemias2
2CompletedTreatmentLeukemias / Malignant Lymphomas1
2CompletedTreatmentLung Cancers1
2CompletedTreatmentLymphoblastic Leukemia, Acute1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2CompletedTreatmentMalignant Neoplasm of Pancreas1
2CompletedTreatmentMesothelioma, Malignant1
2CompletedTreatmentMetastatic Breast Cancer (MBC)1
2CompletedTreatmentMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Salivary Gland Squamous Cell Carcinoma / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IVA Salivary Gland Cancer / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Salivary Gland Cancer / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVB Verrucous Carcinoma of the Oral Cavity / Stage IVC Salivary Gland Cancer / Stage IVC Squamous Cell Carcinoma of the Larynx / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Verrucous Carcinoma of the Larynx / Stage IVC Verrucous Carcinoma of the Oral Cavity / Tongue Cancer1
2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC) / Recurrent Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentPhiladelphia Positive Acute Lymphoblastic Leukemia1
2CompletedTreatmentPolycythemia Vera (PV)1
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
2CompletedTreatmentRecurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
2CompletedTreatmentRecurrent Melanoma / Stage IIIA Melanoma / Stage IIIB Melanoma / Stage IIIC Melanoma / Stage IV Melanoma1
2CompletedTreatmentRecurrent Skin Cancer / Squamous Cell Carcinoma of the Skin / Stage 0 Chronic Lymphocytic Leukemia / Stage I Chronic Lymphocytic Leukemia1
2CompletedTreatmentRelapsed, Refractory or Plateau Phase Multiple Myeloma1
2Enrolling by InvitationTreatmentAcute,Leukemia, Lymphoid1
2Not Yet RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2Not Yet RecruitingTreatmentChronic Myeloid Leukemia (CML)1
2RecruitingNot AvailableChronic Myeloid Leukemia (CML)1
2RecruitingPreventionCancer, Breast1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Refractory Adult Acute Lymphoblastic Leukemia1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative / Philadelphia Chromosome Positive / Recurrent Adult Acute Lymphoblastic Leukemia / Refractory Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Adult Lymphoblastic Lymphoma1
2RecruitingTreatmentAdult Acute Lymphoblastic Leukemia / Adult Lymphoblastic Lymphoma / CD20 Positive / Philadelphia Chromosome Positive1
2RecruitingTreatmentAdvanced Malignant Neoplasm / Advanced Malignant Solid Neoplasm / Bladder Carcinoma / Carcinoma, Breast / Carcinoma, Colorectal / Carcinoma, Pancreatic / Cervical Carcinoma / Colon Carcinoma / Endometrial Carcinoma / Gastric Carcinoma / Gliomas / Head and Neck Carcinoma / Liver and Intrahepatic Bile Duct Carcinoma / Lung, Carcinoma / Malignant Lymphomas / Malignant Uterine Neoplasm / Melanoma / Oesophageal Carcinoma / Ovarian Carcinoma / Plasma Cell Myeloma / Prostate Cancer / Rectal Carcinoma / Recurrent Bladder Carcinoma / Recurrent Breast Carcinoma / Recurrent Cervical Carcinoma / Recurrent Colon Carcinoma / Recurrent Colorectal Carcinoma / Recurrent Esophageal Carcinoma / Recurrent Gastric Carcinoma / Recurrent Gliomas / Recurrent Head and Neck Carcinoma / Recurrent Liver Carcinoma / Recurrent Lung Carcinoma / Recurrent Lymphoma / Recurrent Malignant Solid Neoplasm / Recurrent Melanoma / Recurrent Ovarian Carcinoma / Recurrent Pancreatic Carcinoma / Recurrent Plasma Cell Myeloma / Recurrent Prostate Carcinoma / Recurrent Rectal Carcinoma / Recurrent Skin Carcinoma / Recurrent Solid Neoplasm / Recurrent Thyroid Gland Carcinoma / Recurrent Uterine Corpus Carcinoma / Refractory Lymphomas / Refractory Malignant Neoplasm / Refractory Malignant Solid Neoplasm / Refractory Plasma Cell Myeloma / Renal Carcinoma / Skin Carcinoma / Solid Neoplasms / Thyroid Gland Carcinoma / Uterine Corpus Cancer1
2RecruitingTreatmentAdvanced Solid Tumors / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentCancer, Advanced1
2RecruitingTreatmentChronic Kidney Disease (CKD)1
2RecruitingTreatmentChronic Myelogenous Leukemia (CML) / Chronic Myeloid Leukemia (CML) / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Leukemias1
2RecruitingTreatmentChronic Myeloid Leukemia (CML)1
2RecruitingTreatmentDiffuse Intrinsic Pontine Glioma (DIPG)1
2RecruitingTreatmentLeukemias1
2RecruitingTreatmentMelanoma (Skin)1
2RecruitingTreatmentMetastatic Melanoma1
2RecruitingTreatmentNeoplasms, Breast / Triple Negative Breast Neoplasms1
2RecruitingTreatmentNeuroblastoma Recurrent1
2RecruitingTreatmentPinealoblastoma1
2RecruitingTreatmentProstate Cancer1
2RecruitingTreatmentRefractory Pediatric AML / Refractory Pediatric Solid Tumors / Relapsed Pediatric AML / Relapsed Pediatric Solid Tumors1
2TerminatedTreatmentAdult Primary Hepatocellular Carcinoma / Advanced Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer1
2TerminatedTreatmentCancer, Breast2
2TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
2TerminatedTreatmentChronic Myeloid Leukemia (CML)1
2TerminatedTreatmentLeukemia,Myeloid, Chronic1
2TerminatedTreatmentLung Cancers1
2TerminatedTreatmentMalignant Neoplasm of Pancreas1
2TerminatedTreatmentMelanoma1
2TerminatedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)2
2TerminatedTreatmentPlasma Cell Myeloma1
2TerminatedTreatmentProstate Cancer2
2TerminatedTreatmentSquamous Cell Carcinoma of Lung1
2TerminatedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2Unknown StatusTreatmentCancer, Breast / Metastatic Cancers1
2Unknown StatusTreatmentChronic Lymphocytic Leukaemia (CLL)1
2Unknown StatusTreatmentHormone-Resistant Prostate Cancer / Recurrent Prostate Cancer1
2Unknown StatusTreatmentLeukemias1
2Unknown StatusTreatmentMyelogenous Leukemia, Chronic, Chronic Phase1
2Unknown StatusTreatmentSystemic Mastocytosis1
2WithdrawnTreatmentBrain Diseases / CNS Disease / Glioblastomas1
2WithdrawnTreatmentCancer, Breast1
2, 3CompletedTreatmentAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
2, 3WithdrawnTreatmentAcute Lymphoblastic Leukaemias (ALL) / Chronic Myeloid Leukemia (CML)1
3CompletedTreatmentChronic Myelocytic Leukemia1
3CompletedTreatmentLeukemia, Lymphoblastic, Acute, Philadelphia-Positive / Myeloid Leukemia, Chronic, Accelerated Phase1
3CompletedTreatmentMyeloid Leukemia, Chronic, Chronic-Phase1
3CompletedTreatmentProstatic Neoplasms1
3Not Yet RecruitingTreatmentChronic Myeloid Leukemia - Chronic Phase1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3RecruitingTreatmentAcute Lymphoblastic Leukemia, Pediatric1
3RecruitingTreatmentAcute Myeloid Leukaemias (AML)1
3RecruitingTreatmentChronic Myelocytic Leukemia1
3RecruitingTreatmentChronic Myeloid Leukemia (CML)1
3RecruitingTreatmentMyeloid Leukemia, Chronic, Chronic Phase1
3SuspendedTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Ph-Like Acute Lymphoblastic Leukemia / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3TerminatedTreatmentLeukemias1
4CompletedTreatmentChronic Phase Chronic Myeloid Leukemia1
4Not Yet RecruitingTreatmentPh+ Acute Lymphoblastic Leukemia1
4RecruitingTreatmentChronic Myelogenous Leukemia (CML)2
Not AvailableActive Not RecruitingDiagnosticAdvanced Solid Tumors / Cancers1
Not AvailableActive Not RecruitingTreatmentRecurrent Childhood Brain Tumor1
Not AvailableApproved for MarketingNot AvailableLeukemias1
Not AvailableAvailableNot AvailableChronic Myeloid Leukemia (CML)1
Not AvailableCompletedNot AvailableChronic Myeloid Leukemia (CML)1
Not AvailableCompletedNot AvailableLeukemia, Myelogenous, Chronic, BCR-ABL Positive1
Not AvailableCompletedNot AvailableLeukemia, Myeloid, Chronic-Phase (CML-CP)1
Not AvailableCompletedNot AvailableLeukemias / Lung Cancer Small Cell Lung Cancer (SCLC)1
Not AvailableCompletedNot AvailableLiver Diseases1
Not AvailableCompletedTreatmentMyelodysplastic Syndromes1
Not AvailableCompletedTreatmentTransitional Cell Carcinoma of the Bladder1
Not AvailableRecruitingTreatmentAcute Myeloid Leukaemias (AML)1
Not AvailableRecruitingTreatmentGastrointestinal Stromal Tumors1
Not AvailableRecruitingTreatmentHematopoietic Stem Cell Transplant (HSCT)1
Not AvailableWithdrawnNot AvailableLeukemia, Myelogenous, Chronic, BCR-ABL Positive1
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral100 mg/1
TabletOral100 mg
TabletOral140 mg/1
TabletOral140 mg
TabletOral20 mg/1
TabletOral20 mg
TabletOral50 mg/1
TabletOral50 mg
TabletOral70 mg/1
TabletOral70 mg
TabletOral80 mg
TabletOral80 mg/1
Tablet, film coatedOral100 mg
Tablet, film coatedOral140 mg
Tablet, film coatedOral20 mg
Tablet, film coatedOral50 mg
Tablet, film coatedOral70 mg
Tablet, film coatedOral80 mg
Prices
Unit descriptionCostUnit
Sprycel 100 mg tablet278.24USD tablet
Sprycel 50 mg tablet139.12USD tablet
Sprycel 70 mg tablet139.12USD tablet
Sprycel 20 mg tablet69.56USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2366932 No2009-08-252020-04-12Canada
US6596746 No2000-06-282020-06-28Us
US7125875 No2000-04-132020-04-13Us
US7153856 No2000-04-282020-04-28Us
US7491725 No2006-03-282026-03-28Us
US8680103 No2005-02-042025-02-04Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)280-286 °CNot Available
logP1.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0128 mg/mLALOGPS
logP2.77ALOGPS
logP3.82ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)8.49ChemAxon
pKa (Strongest Basic)7.22ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area106.51 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity133.08 m3·mol-1ChemAxon
Polarizability51.58 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9852
Blood Brain Barrier-0.507
Caco-2 permeable-0.5638
P-glycoprotein substrateSubstrate0.6562
P-glycoprotein inhibitor IInhibitor0.5371
P-glycoprotein inhibitor IIInhibitor0.5425
Renal organic cation transporterNon-inhibitor0.7288
CYP450 2C9 substrateNon-substrate0.7061
CYP450 2D6 substrateNon-substrate0.8152
CYP450 3A4 substrateSubstrate0.5704
CYP450 1A2 substrateNon-inhibitor0.5612
CYP450 2C9 inhibitorInhibitor0.8008
CYP450 2D6 inhibitorNon-inhibitor0.8358
CYP450 2C19 inhibitorInhibitor0.574
CYP450 3A4 inhibitorInhibitor0.7295
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8343
Ames testNon AMES toxic0.7185
CarcinogenicityNon-carcinogens0.7308
BiodegradationNot ready biodegradable0.9863
Rat acute toxicity2.4772 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8538
hERG inhibition (predictor II)Inhibitor0.718
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-000m-0390000000-8a413cb9e53d14cbe10aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-000i-0011900000-4dac51b915117532ebe0View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aromatic anilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with an aromatic group. They have the general structure RNC(=O)R', where R= benzene, and R = aryl group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassAnilides
Direct ParentAromatic anilides
Alternative ParentsN-arylpiperazines / Thiazolecarboxamides / 2-heteroaryl carboxamides / Dialkylarylamines / 2,5-disubstituted thiazoles / Toluenes / Aminopyrimidines and derivatives / Chlorobenzenes / N-alkylpiperazines / 2-amino-1,3-thiazoles
SubstituentsAromatic anilide / N-arylpiperazine / 2-heteroaryl carboxamide / Thiazolecarboxamide / Thiazolecarboxylic acid or derivatives / Dialkylarylamine / Halobenzene / 2,5-disubstituted 1,3-thiazole / Chlorobenzene / Aminopyrimidine
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptorstertiary amino compound, N-arylpiperazine, N-(2-hydroxyethyl)piperazine, aminopyrimidine, monocarboxylic acid amide, organochlorine compound, 1,3-thiazole, secondary amino compound (CHEBI:49375 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
multitarget
General Function:
Syntaxin binding
Specific Function:
Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 ...
Gene Name:
ABL1
Uniprot ID:
P00519
Uniprot Name:
Tyrosine-protein kinase ABL1
Molecular Weight:
122871.435 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  2. Piccaluga PP, Paolini S, Martinelli G: Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer. 2007 Sep 15;110(6):1178-86. [PubMed:17701954 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
multitarget
General Function:
Sh3/sh2 adaptor activity
Specific Function:
Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors as well as cytokine receptors. Participates in signaling pathways that control a diverse spectrum of biological activities including...
Gene Name:
SRC
Uniprot ID:
P12931
Uniprot Name:
Proto-oncogene tyrosine-protein kinase Src
Molecular Weight:
59834.295 Da
References
  1. Kamath AV, Wang J, Lee FY, Marathe PH: Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol. 2008 Mar;61(3):365-76. Epub 2007 Apr 11. [PubMed:17429625 ]
  2. Serrels A, Macpherson IR, Evans TR, Lee FY, Clark EA, Sansom OJ, Ashton GH, Frame MC, Brunton VG: Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther. 2006 Dec;5(12):3014-22. Epub 2006 Dec 5. [PubMed:17148760 ]
  3. Quintas-Cardama A, Kantarjian H, Cortes J: Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib. Future Oncol. 2006 Dec;2(6):655-65. [PubMed:17155893 ]
  4. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006 Jan 1;66(1):473-81. [PubMed:16397263 ]
  5. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J, Lee FY, Jove R: Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005 Oct 15;65(20):9185-9. [PubMed:16230377 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Activated by the lig...
Gene Name:
EPHA2
Uniprot ID:
P29317
Uniprot Name:
Ephrin type-A receptor 2
Molecular Weight:
108265.585 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [PubMed:20072833 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
multitarget
General Function:
Sh2 domain binding
Specific Function:
Non-receptor tyrosine-protein kinase that plays an essential role in the selection and maturation of developing T-cells in the thymus and in the function of mature T-cells. Plays a key role in T-cell antigen receptor (TCR)-linked signal transduction pathways. Constitutively associated with the cytoplasmic portions of the CD4 and CD8 surface receptors. Association of the TCR with a peptide antig...
Gene Name:
LCK
Uniprot ID:
P06239
Uniprot Name:
Tyrosine-protein kinase Lck
Molecular Weight:
58000.15 Da
References
  1. Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC: 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem. 2006 Nov 16;49(23):6819-32. [PubMed:17154512 ]
  2. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [PubMed:20072833 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Receptor binding
Specific Function:
Non-receptor protein tyrosine kinase that is involved in the regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling, and differentiation. Stimulation by receptor tyrosine kinases (RTKs) including EGRF, PDGFR, CSF1R and FGFR leads to recruitment of YES1 to the phosphorylated receptor, and activation and phosphorylation of downstream substrates. Upon EGFR a...
Gene Name:
YES1
Uniprot ID:
P07947
Uniprot Name:
Tyrosine-protein kinase Yes
Molecular Weight:
60800.78 Da
References
  1. Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY, Donato NJ, Abbruzzese JL, Baker CH, Gallick GE: Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol. 2006 Mar;168(3):962-72. [PubMed:16507911 ]
  2. Margutti S, Laufer SA: Are MAP kinases drug targets? Yes, but difficult ones. ChemMedChem. 2007 Aug;2(8):1116-40. [PubMed:17541990 ]
  3. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [PubMed:20072833 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1...
Gene Name:
KIT
Uniprot ID:
P10721
Uniprot Name:
Mast/stem cell growth factor receptor Kit
Molecular Weight:
109863.655 Da
References
  1. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006 Jan 1;66(1):473-81. [PubMed:16397263 ]
  2. Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C: Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006 Jul 1;108(1):286-91. Epub 2006 Jan 24. [PubMed:16434489 ]
  3. Dizdar O, Dede DS, Bulut N, Altundag K: Dasatinib may also inhibit c-Kit in triple negative breast cancer cell lines. Breast Cancer Res Treat. 2008 Jan;107(2):303. Epub 2007 Mar 10. [PubMed:17351742 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Vascular endothelial growth factor binding
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of peri...
Gene Name:
PDGFRB
Uniprot ID:
P09619
Uniprot Name:
Platelet-derived growth factor receptor beta
Molecular Weight:
123966.895 Da
References
  1. Zhang Z, Meier KE: New assignments for multitasking signal transduction inhibitors. Mol Pharmacol. 2006 May;69(5):1510-2. Epub 2006 Feb 23. [PubMed:16497876 ]
  2. Chen Z, Lee FY, Bhalla KN, Wu J: Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol. 2006 May;69(5):1527-33. Epub 2006 Jan 25. [PubMed:16436588 ]
  3. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [PubMed:20072833 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transcription factor activity, sequence-specific dna binding
Specific Function:
Carries out a dual function: signal transduction and activation of transcription. Mediates cellular responses to the cytokine KITLG/SCF and other growth factors. Binds to the GAS element and activates PRL-induced transcription.
Gene Name:
STAT5B
Uniprot ID:
P51692
Uniprot Name:
Signal transducer and activator of transcription 5B
Molecular Weight:
89865.35 Da
References
  1. Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K: Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res. 2006 Oct 1;12(19):5869-78. [PubMed:17020995 ]
  2. Nam S, Williams A, Vultur A, List A, Bhalla K, Smith D, Lee FY, Jove R: Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther. 2007 Apr;6(4):1400-5. [PubMed:17431118 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
multitarget
General Function:
Receptor binding
Specific Function:
Non-receptor tyrosine-protein kinase that plays an ABL1-overlapping role in key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion and receptor endocytosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like MYH10 (involved in movement); CTTN (...
Gene Name:
ABL2
Uniprot ID:
P42684
Uniprot Name:
Abelson tyrosine-protein kinase 2
Molecular Weight:
128341.935 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  2. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [PubMed:20072833 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
multitarget
General Function:
Protein tyrosine kinase activity
Specific Function:
Non-receptor tyrosine-protein kinase that plays a role in many biological processes including regulation of cell growth and survival, cell adhesion, integrin-mediated signaling, cytoskeletal remodeling, cell motility, immune response and axon guidance. Inactive FYN is phosphorylated on its C-terminal tail within the catalytic domain. Following activation by PKA, the protein subsequently associa...
Gene Name:
FYN
Uniprot ID:
P06241
Uniprot Name:
Tyrosine-protein kinase Fyn
Molecular Weight:
60761.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [PubMed:20072833 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein tyrosine kinase activity
Specific Function:
Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. After BCR engagement and activation at the plasma membrane, phosphorylates PLCG2 at several sites, igniting the downstream signaling pathway through calcium mobilization, fol...
Gene Name:
BTK
Uniprot ID:
Q06187
Uniprot Name:
Tyrosine-protein kinase BTK
Molecular Weight:
76280.71 Da
References
  1. Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G, Colinge J, Bennett KL, Ellmeier W, Valent P, Superti-Furga G: The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13283-8. Epub 2007 Aug 7. [PubMed:17684099 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Transcriptional activator that binds to regulatory elements in promoter regions in a cell- and response element (target)-specific manner. Induces gene expression by binding as monomers to the NR4A1 response element (NBRE) 5'-AAAAGGTCA-3' site and as homodimers to the Nur response element (NurRE) site in the promoter of their regulated target genes (By similarity). Plays a role in the regulation of proliferation, survival and differentiation of many different cell types and also in metabolism and inflammation. Mediates proliferation of vascular smooth muscle, myeloid progenitor cell and type B pancreatic cells; promotes mitogen-induced vascular smooth muscle cell proliferation through transactivation of SKP2 promoter by binding a NBRE site (By similarity). Upon PDGF stimulation, stimulates vascular smooth muscle cell proliferation by regulating CCND1 and CCND2 expression. In islets, induces type B pancreatic cell proliferation through up-regulation of genes that activate cell cycle, as well as genes that cause degradation of the CDKN1A (By similarity). Negatively regulates myeloid progenitor cell proliferation by repressing RUNX1 in a NBRE site-independent manner. During inner ear, plays a role as a key mediator of the proliferative growth phase of semicircular canal development (By similarity). Mediates also survival of neuron and smooth muscle cells; mediates CREB-induced neuronal survival, and during hippocampus development, plays a critical role in pyramidal cell survival and axonal guidance. Is required for S phase entry of the cell cycle and survival of smooth muscle cells by inducing CCND1, resulting in RB1 phosphorylation. Binds to NBRE motif in CCND1 promoter, resulting in the activation of the promoter and CCND1 transcription (By similarity). Plays also a role in inflammation; upon TNF stimulation, mediates monocyte adhesion by inducing the expression of VCAM1 and ICAM1 by binding to the NBRE consensus site (By similarity) (PubMed:20558821). In mast cells activated by Fc-epsilon receptor cross-linking, promotes the synthesis and release of cytokines but impairs events leading to degranulation (By similarity). Plays also a role in metabolism; by modulating feeding behavior; and by playing a role in energy balance by inhibiting the glucocorticoid-induced orexigenic neuropeptides AGRP expression, at least in part by forming a complex with activated NR3C1 on the AGRP- glucocorticoid response element (GRE), and thus weakening the DNA binding activity of NR3C1. Upon catecholamines stimulation, regulates gene expression that controls oxidative metabolism in skeletal muscle (By similarity). Plays a role in glucose transport by regulating translocation of the SLC2A4 glucose transporter to the cell surface (PubMed:24022864). Finally, during gastrulation plays a crucial role in the formation of anterior mesoderm by controlling cell migration. Inhibits adipogenesis (By similarity). Also participates in cardiac hypertrophy by activating PARP1 (By similarity).
Specific Function:
Core promoter sequence-specific dna binding
Gene Name:
NR4A3
Uniprot ID:
Q92570
Uniprot Name:
Nuclear receptor subfamily 4 group A member 3
Molecular Weight:
68229.025 Da
References
  1. Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G, Colinge J, Bennett KL, Ellmeier W, Valent P, Superti-Furga G: The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13283-8. Epub 2007 Aug 7. [PubMed:17684099 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Rho guanyl-nucleotide exchange factor activity
Specific Function:
GTPase-activating protein for RAC1 and CDC42. Promotes the exchange of RAC or CDC42-bound GDP by GTP, thereby activating them. Displays serine/threonine kinase activity.
Gene Name:
BCR
Uniprot ID:
P11274
Uniprot Name:
Breakpoint cluster region protein
Molecular Weight:
142818.07 Da
References
  1. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004 Jul 16;305(5682):399-401. [PubMed:15256671 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Receptor binding
Specific Function:
Non-receptor tyrosine-protein kinase that plays an important role in the regulation of cell growth, differentiation, migration and immune response. Phosphorylates tyrosine residues located in the C-terminal tails of Src-family kinases (SFKs) including LCK, SRC, HCK, FYN, LYN or YES1. Upon tail phosphorylation, Src-family members engage in intramolecular interactions between the phosphotyrosine ...
Gene Name:
CSK
Uniprot ID:
P41240
Uniprot Name:
Tyrosine-protein kinase CSK
Molecular Weight:
50703.975 Da
References
  1. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7. [PubMed:18180381 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Transmembrane-ephrin receptor activity
Specific Function:
Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Among GPI-anchored eph...
Gene Name:
EPHA5
Uniprot ID:
P54756
Uniprot Name:
Ephrin type-A receptor 5
Molecular Weight:
114802.31 Da
References
  1. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7. [PubMed:18180381 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Together with its cog...
Gene Name:
EPHB4
Uniprot ID:
P54760
Uniprot Name:
Ephrin type-B receptor 4
Molecular Weight:
108269.26 Da
References
  1. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7. [PubMed:18180381 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein tyrosine kinase activity
Specific Function:
Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors devoid of kinase activity and contributes to the regulation of immune responses, including neutrophil, monocyte, macrophage and mast cell functions, cytoskeleton remodeling in response to extracellular stimuli, phagocytosis, cell adhesion and migration. Promotes mast cell degranulation, release of inflammato...
Gene Name:
FGR
Uniprot ID:
P09769
Uniprot Name:
Tyrosine-protein kinase Fgr
Molecular Weight:
59478.11 Da
References
  1. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7. [PubMed:18180381 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Receptor binding
Specific Function:
Non-receptor tyrosine-protein kinase that negatively regulates cell proliferation. Positively regulates PTEN protein stability through phosphorylation of PTEN on 'Tyr-336', which in turn prevents its ubiquitination and degradation, possibly by reducing its binding to NEDD4. May function as a tumor suppressor.
Gene Name:
FRK
Uniprot ID:
P42685
Uniprot Name:
Tyrosine-protein kinase FRK
Molecular Weight:
58253.61 Da
References
  1. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7. [PubMed:18180381 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Unfolded protein binding
Specific Function:
Acts as a repressor of transcriptional activation. Inhibits the transcriptional coactivator activity of CITED1 on Smad-mediated transcription. Chaperone. Component of the PRP19-CDC5L complex that forms an integral part of the spliceosome and is required for activating pre-mRNA splicing. May have a scaffolding role in the spliceosome assembly as it contacts all other components of the core compl...
Gene Name:
HSPA8
Uniprot ID:
P11142
Uniprot Name:
Heat shock cognate 71 kDa protein
Molecular Weight:
70897.565 Da
References
  1. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7. [PubMed:18180381 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Receptor signaling protein tyrosine kinase activity
Specific Function:
Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors and plays an important role in the regulation of innate and adaptive immune responses, hematopoiesis, responses to growth factors and cytokines, integrin signaling, but also responses to DNA damage and genotoxic agents. Functions primarily as negative regulator, but can also function as activator, depending ...
Gene Name:
LYN
Uniprot ID:
P07948
Uniprot Name:
Tyrosine-protein kinase Lyn
Molecular Weight:
58573.595 Da
References
  1. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7. [PubMed:18180381 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein serine/threonine kinase activity
Specific Function:
Stress-activated component of a protein kinase signal transduction cascade. Regulates the JNK and p38 pathways. Pro-apoptotic. Role in regulation of S and G2 cell cycle checkpoint by direct phosphorylation of CHEK2. Isoform 1, but not isoform 2, causes cell shrinkage and disruption of actin stress fibers. Isoform 1 may have role in neoplastic cell transformation and cancer development. Isoform ...
Gene Name:
ZAK
Uniprot ID:
Q9NYL2
Uniprot Name:
Mitogen-activated protein kinase kinase kinase MLT
Molecular Weight:
91154.315 Da
References
  1. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7. [PubMed:18180381 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein serine/threonine kinase activity
Specific Function:
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK14 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors. Accordingly, p38 MAPKs phosphorylate a broad r...
Gene Name:
MAPK14
Uniprot ID:
Q16539
Uniprot Name:
Mitogen-activated protein kinase 14
Molecular Weight:
41292.885 Da
References
  1. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7. [PubMed:18180381 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Metal ion binding
Specific Function:
Not Available
Gene Name:
PPAT
Uniprot ID:
Q06203
Uniprot Name:
Amidophosphoribosyltransferase
Molecular Weight:
57398.52 Da
References
  1. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7. [PubMed:18180381 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Uniprot Name:
Cytochrome P450 3A4
Molecular Weight:
57342.67 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  2. Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D: Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39. doi: 10.1124/dmd.107.020255. Epub 2008 Jun 12. [PubMed:18556438 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Uniprot Name:
Cytochrome P450 1A1
Molecular Weight:
58164.815 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  2. Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D: Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39. doi: 10.1124/dmd.107.020255. Epub 2008 Jun 12. [PubMed:18556438 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Uniprot Name:
Cytochrome P450 1A2
Molecular Weight:
58293.76 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  2. Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D: Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39. doi: 10.1124/dmd.107.020255. Epub 2008 Jun 12. [PubMed:18556438 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Uniprot Name:
Cytochrome P450 1B1
Molecular Weight:
60845.33 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  2. Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D: Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39. doi: 10.1124/dmd.107.020255. Epub 2008 Jun 12. [PubMed:18556438 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Uniprot Name:
Cytochrome P450 3A5
Molecular Weight:
57108.065 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  2. Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D: Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39. doi: 10.1124/dmd.107.020255. Epub 2008 Jun 12. [PubMed:18556438 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Trimethylamine monooxygenase activity
Specific Function:
Involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. It N-oxygenates primary aliphatic alkylamines as well as secondary and tertiary amines. Plays an important role in the metabolism of trimethylamine (TMA), via the production of TMA N-oxide (TMAO). Is also able to perform S-oxidation when acting on sulfide compounds (PubMed:9224773).
Gene Name:
FMO3
Uniprot ID:
P31513
Uniprot Name:
Dimethylaniline monooxygenase [N-oxide-forming] 3
Molecular Weight:
60032.975 Da
References
  1. Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D: Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39. doi: 10.1124/dmd.107.020255. Epub 2008 Jun 12. [PubMed:18556438 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Uniprot Name:
Multidrug resistance protein 1
Molecular Weight:
141477.255 Da
References
  1. Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80. doi: 10.1124/dmd.109.031302. Epub 2010 Apr 27. [PubMed:20423956 ]
  2. Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64. doi: 10.1111/j.1476-5381.2009.00383.x. Epub 2009 Sep 28. [PubMed:19785662 ]
  3. Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE: Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood. 2008 Oct 15;112(8):3348-54. doi: 10.1182/blood-2007-10-116236. Epub 2008 Jul 31. [PubMed:18669873 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Uniprot Name:
ATP-binding cassette sub-family G member 2
Molecular Weight:
72313.47 Da
References
  1. Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80. doi: 10.1124/dmd.109.031302. Epub 2010 Apr 27. [PubMed:20423956 ]
  2. Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64. doi: 10.1111/j.1476-5381.2009.00383.x. Epub 2009 Sep 28. [PubMed:19785662 ]
Drug created on May 08, 2007 18:32 / Updated on September 01, 2017 10:38